The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.
about
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsMolecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Molecular pathology of non-small cell lung cancer: a practical guide.Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in GermanyUsing multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized MedicineCrizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Aligning the economic value of companion diagnostics and stratified medicines.Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and TreatmentBuyer beware: understanding the assumptions behind health economic assessments in personalized cancer care.Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in EuropePET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging.Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer.Controversies in the management of brain metastasesTissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkersImpact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in CanadaDiagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Treating ALK-positive lung cancer--early successes and future challenges.Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.Molecular pathology in lung cancer: a guide to the techniques used in clinical practice.Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.Integration of phytochemicals and phytotherapy into cancer precision medicine.ALK alterations and inhibition in lung cancer.Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation.Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer.Personalized psychiatry: many questions, fewer answers.A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies.Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
P2860
Q26740329-13D7ED98-9FB3-45CD-A6DF-8D972C7D730AQ26825512-0140118A-2AB6-40CB-945B-0C799DBBAF90Q27690919-4BFF6D82-D46B-4E73-8982-38A80C3E0B94Q28072203-DD22FBF0-BA37-45B9-8179-9289D1EC9C5FQ34175045-E4A99D7F-71CC-49FA-8549-0793678ED4B6Q34219452-112818FA-8BB4-4537-A012-71006CA5D03DQ34388696-774BBBAE-DE1F-4C58-B31C-F828F9F88501Q34431889-AC338ADC-1869-4DFE-A076-C2C23D53FBE4Q34608624-C3385615-F172-410F-AE26-0B2DC3373FF2Q34662576-059A19A1-B52D-4286-9312-75FA180E2ED9Q34814396-52648581-FA58-4D89-BD65-D44BEDD7B837Q35394529-B6ECDB5C-103A-41E2-9EE6-469354CAA2EFQ35824470-5C5177F9-1238-49EA-AB2D-2862A9D5E248Q36357752-41B81873-3763-4C1D-9BDB-F3B56E15A43AQ36731901-33D3E20D-4102-4CA0-9B9E-B98382E2AD3FQ36851177-B1E1EC97-394B-47B5-8DA8-42A43D1A43EAQ36931470-1127EBDF-04CB-4197-B2A4-57FB7F09EC02Q36962487-821DADA0-5BF2-4C82-8BE9-74AF1A8665F8Q37056876-334BA2E0-0C8D-4856-9AEF-99F780ED2776Q37604076-713F3243-0860-4914-B98E-011B2948A1B0Q37999657-14D662B7-5251-4DC1-89C5-BFBAEBEE7448Q38002887-D71D00AC-675F-41ED-89E7-012E980634E4Q38096472-5177C3E1-A334-4DAC-B969-287CE2B1AB33Q38101614-F7BF7186-FC55-4A98-B0E8-37493EC682EAQ38240593-07FE7094-1032-4DE4-931D-C2594BE0A370Q38241120-F6E4EDED-1B11-4095-82B5-7D699B58CA57Q38241709-B332EFA9-64A2-4F21-9876-F0C1B4B8E1F6Q38352879-AA1A52EC-2EFF-48AE-AAD8-5FA19B37ED46Q38386866-564F9A05-E19D-447A-9CB3-00EC33E50CB2Q38528130-E4BFB8EF-9B9D-4E5C-A799-24EDAA0996E6Q38780465-D718FCBF-0BD2-473D-82B6-98D9A556D287Q38820412-83D6B61F-26A8-4EF0-B6D7-6893F5F69A57Q39210850-2C9064BF-1331-4C40-A874-BC4D1A656457Q41701893-5CA50D00-9B7A-4802-B878-AFAF816C0E1AQ42650792-0039528D-A13B-4A30-B42D-4E60C6A28756Q42919995-E4692B10-549D-4AE8-B146-93D20D5FE590Q45061286-3D856F9A-05B7-45A3-8333-8CFC43D75BDCQ46762821-DBA7C092-3D30-4780-8661-39402B2513BFQ46990602-ABF965E0-D3B4-4021-9513-466CA1AF2E19Q50238133-199C31BF-8533-400A-9A36-891AE2351B55
P2860
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The cost-effectiveness of scre ...... eted drug sensitivity markers.
@ast
The cost-effectiveness of scre ...... eted drug sensitivity markers.
@en
type
label
The cost-effectiveness of scre ...... eted drug sensitivity markers.
@ast
The cost-effectiveness of scre ...... eted drug sensitivity markers.
@en
prefLabel
The cost-effectiveness of scre ...... eted drug sensitivity markers.
@ast
The cost-effectiveness of scre ...... eted drug sensitivity markers.
@en
P2860
P356
P1476
The cost-effectiveness of scre ...... eted drug sensitivity markers.
@en
P2093
A J Atherly
D R Camidge
P2860
P2888
P304
P356
10.1038/BJC.2012.60
P407
P577
2012-02-28T00:00:00Z